{"transactions":[{"id":4636384,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":184259,"kind":"person","name":"Rubino Ivana","position":1,"cik":"0002157418","reported_name":"Rubino Ivana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option (right to buy)","published_at":"2026-10-06T21:04:53.000Z","date":"2026-10-05","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest on October 5, 2026, with the remaining shares vesting monthly over the three (3) years thereafter, subject to continued service to the Issuer through each vesting date."}],"balance_after":80000,"derivative":{"exercise_price":9.37,"expiration_date":"2036-10-05","underlying":"Common Shares","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-26-114106","document":"tm2627035-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2157418/000110465926114106/tm2627035-2_4seq1.xml","form_type":"4"}},{"id":692967,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":25410,"kind":"person","name":"Kaplan Johanne","position":1,"cik":"0001967717","reported_name":"Kaplan Johanne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Shares","published_at":"2026-08-07T20:00:13.000Z","date":"2026-08-05","kind":"purchase","planned":false,"acquired":true,"shares":2280,"price":13.3,"value":30324.0,"ownership":{"direct":true},"balance_after":6221,"source":{"system":"sec-edgar","filing":"0001104659-26-092673","document":"tm2622584-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926092673/tm2622584-1_4seq1.xml","form_type":"4"}},{"id":766630,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44879,"kind":"person","name":"WYMAN WILLIAM W","position":1,"cik":"0001077644","reported_name":"WYMAN WILLIAM W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-05-22T20:35:46.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board."}],"balance_after":11000,"derivative":{"exercise_price":10.77,"expiration_date":"2036-05-20","underlying":"Common Shares","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001104659-26-065775","document":"tm2615475-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1077644/000110465926065775/tm2615475-9_4seq1.xml","form_type":"4"}},{"id":766629,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44879,"kind":"person","name":"WYMAN WILLIAM W","position":1,"cik":"0001077644","reported_name":"WYMAN WILLIAM W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-05-22T20:35:46.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board."}],"balance_after":5500,"derivative":{"exercise_price":10.77,"expiration_date":"2036-05-20","underlying":"Common Shares","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001104659-26-065775","document":"tm2615475-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1077644/000110465926065775/tm2615475-9_4seq1.xml","form_type":"4"}},{"id":765717,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44680,"kind":"person","name":"Williams Eugene","position":1,"cik":"0001927626","reported_name":"Williams Eugene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-05-22T20:35:15.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board."}],"balance_after":11000,"derivative":{"exercise_price":10.77,"expiration_date":"2036-05-20","underlying":"Common Shares","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001104659-26-065774","document":"tm2615475-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926065774/tm2615475-8_4seq1.xml","form_type":"4"}},{"id":765716,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44680,"kind":"person","name":"Williams Eugene","position":1,"cik":"0001927626","reported_name":"Williams Eugene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-05-22T20:35:15.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board."}],"balance_after":5500,"derivative":{"exercise_price":10.77,"expiration_date":"2036-05-20","underlying":"Common Shares","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001104659-26-065774","document":"tm2615475-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926065774/tm2615475-8_4seq1.xml","form_type":"4"}},{"id":765778,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44688,"kind":"person","name":"Warma Neil K","position":1,"cik":"0001437911","reported_name":"Warma Neil K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2026-05-22T20:34:42.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date."}],"balance_after":160000,"derivative":{"exercise_price":10.77,"expiration_date":"2036-05-20","underlying":"Common Shares","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001104659-26-065772","document":"tm2615475-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437911/000110465926065772/tm2615475-7_4seq1.xml","form_type":"4"}},{"id":765715,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44679,"kind":"person","name":"Shafmaster Madge K.","position":1,"cik":"0001927066","reported_name":"Shafmaster Madge K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-05-22T20:34:08.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board."}],"balance_after":11000,"derivative":{"exercise_price":10.77,"expiration_date":"2036-05-20","underlying":"Common Shares","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001104659-26-065771","document":"tm2615475-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926065771/tm2615475-6_4seq1.xml","form_type":"4"}},{"id":765714,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44679,"kind":"person","name":"Shafmaster Madge K.","position":1,"cik":"0001927066","reported_name":"Shafmaster Madge K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-05-22T20:34:08.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board."}],"balance_after":5500,"derivative":{"exercise_price":10.77,"expiration_date":"2036-05-20","underlying":"Common Shares","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001104659-26-065771","document":"tm2615475-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926065771/tm2615475-6_4seq1.xml","form_type":"4"}},{"id":765713,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44678,"kind":"person","name":"Cashman Neil","position":1,"cik":"0001927064","reported_name":"Cashman Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2026-05-22T20:33:32.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":10.77,"expiration_date":"2036-05-20","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-065769","document":"tm2615475-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926065769/tm2615475-5_4seq1.xml","form_type":"4"}},{"id":765712,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44677,"kind":"person","name":"Milbury Max A.","position":1,"cik":"0001927056","reported_name":"Milbury Max A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Option (right to buy)","published_at":"2026-05-22T20:31:52.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":18167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date."}],"balance_after":18167,"derivative":{"exercise_price":10.77,"expiration_date":"2036-05-20","underlying":"Common Shares","underlying_shares":18167},"source":{"system":"sec-edgar","filing":"0001104659-26-065766","document":"tm2615475-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926065766/tm2615475-4_4seq1.xml","form_type":"4"}},{"id":766257,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":26284,"kind":"person","name":"Mandel-Brehm Josh","position":1,"cik":"0001927058","reported_name":"Mandel-Brehm Josh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-05-22T20:31:04.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board."}],"balance_after":11000,"derivative":{"exercise_price":10.77,"expiration_date":"2036-05-20","underlying":"Common Shares","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001104659-26-065763","document":"tm2615475-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1927058/000110465926065763/tm2615475-3_4seq1.xml","form_type":"4"}},{"id":766256,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":26284,"kind":"person","name":"Mandel-Brehm Josh","position":1,"cik":"0001927058","reported_name":"Mandel-Brehm Josh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-05-22T20:31:04.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board."}],"balance_after":5500,"derivative":{"exercise_price":10.77,"expiration_date":"2036-05-20","underlying":"Common Shares","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001104659-26-065763","document":"tm2615475-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927058/000110465926065763/tm2615475-3_4seq1.xml","form_type":"4"}},{"id":765709,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":25410,"kind":"person","name":"Kaplan Johanne","position":1,"cik":"0001967717","reported_name":"Kaplan Johanne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Option (right to buy)","published_at":"2026-05-22T20:30:42.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":10.77,"expiration_date":"2036-05-20","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-065762","document":"tm2615475-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926065762/tm2615475-2_4seq1.xml","form_type":"4"}},{"id":765711,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44676,"kind":"person","name":"Alex Slanix Paul","position":1,"cik":"0002092283","reported_name":"Alex Slanix Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-05-22T20:30:20.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board."}],"balance_after":11000,"derivative":{"exercise_price":10.77,"expiration_date":"2036-05-20","underlying":"Common Shares","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001104659-26-065755","document":"tm2615475-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926065755/tm2615475-1_4seq1.xml","form_type":"4"}},{"id":765710,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44676,"kind":"person","name":"Alex Slanix Paul","position":1,"cik":"0002092283","reported_name":"Alex Slanix Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-05-22T20:30:20.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board."}],"balance_after":5500,"derivative":{"exercise_price":10.77,"expiration_date":"2036-05-20","underlying":"Common Shares","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001104659-26-065755","document":"tm2615475-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926065755/tm2615475-1_4seq1.xml","form_type":"4"}},{"id":801772,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":51471,"kind":"person","name":"Kirwin Patrick D.","position":1,"cik":"0001927062","reported_name":"Kirwin Patrick D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-04-24T01:25:00.000Z","date":"2026-04-22","kind":"purchase","planned":false,"acquired":true,"shares":4000,"price":11.33,"value":45320.0,"ownership":{"direct":false,"nature":"By Patrick D. Kirwin Professional Corp"},"balance_after":4653,"source":{"system":"sec-edgar","filing":"0001104659-26-047977","document":"tm2612640-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926047977/tm2612640-1_4seq1.xml","form_type":"4"}},{"id":855710,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44680,"kind":"person","name":"Williams Eugene","position":1,"cik":"0001927626","reported_name":"Williams Eugene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-03-06T12:28:00.000Z","date":"2026-03-05","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":24.4,"value":48800.0,"ownership":{"direct":true},"balance_after":12397,"source":{"system":"sec-edgar","filing":"0001374339-26-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000137433926000004/primary_doc.xml","form_type":"4"}},{"id":861149,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44680,"kind":"person","name":"Williams Eugene","position":1,"cik":"0001927626","reported_name":"Williams Eugene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-03-04T23:08:32.000Z","date":"2026-03-04","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":24,"value":48000.0,"ownership":{"direct":true},"balance_after":10397,"source":{"system":"sec-edgar","filing":"0001374339-26-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000137433926000003/primary_doc.xml","form_type":"4"}},{"id":861148,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44680,"kind":"person","name":"Williams Eugene","position":1,"cik":"0001927626","reported_name":"Williams Eugene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-03-04T23:08:32.000Z","date":"2026-03-03","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":21.89,"value":21890.0,"ownership":{"direct":true},"balance_after":8397,"source":{"system":"sec-edgar","filing":"0001374339-26-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000137433926000003/primary_doc.xml","form_type":"4"}},{"id":861147,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44680,"kind":"person","name":"Williams Eugene","position":1,"cik":"0001927626","reported_name":"Williams Eugene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-03-04T23:08:32.000Z","date":"2026-03-02","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":22.53,"value":22530.0,"ownership":{"direct":true},"balance_after":7397,"source":{"system":"sec-edgar","filing":"0001374339-26-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000137433926000003/primary_doc.xml","form_type":"4"}},{"id":887878,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":25410,"kind":"person","name":"Kaplan Johanne","position":1,"cik":"0001967717","reported_name":"Kaplan Johanne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Shares","published_at":"2026-02-23T13:31:05.000Z","date":"2026-02-19","kind":"purchase","planned":false,"acquired":true,"shares":1629,"price":15.35,"value":25005.15,"ownership":{"direct":true},"balance_after":3941,"source":{"system":"sec-edgar","filing":"0001374339-26-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000137433926000002/primary_doc.xml","form_type":"4"}},{"id":917586,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44678,"kind":"person","name":"Cashman Neil","position":1,"cik":"0001927064","reported_name":"Cashman Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Warrants to purchase Common Shares","published_at":"2026-02-06T01:41:16.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":4122,"ownership":{"direct":false,"nature":"By Research Capital Corporation"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 4,122 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 4,122 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 4,122 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 4,122 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":4122,"derivative":{"exercise_price":14.4,"exercise_date":"2026-02-03","expiration_date":"2031-02-03","underlying":"Common Shares","underlying_shares":4122},"source":{"system":"sec-edgar","filing":"0001104659-26-011140","document":"tm265402-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926011140/tm265402-5_4seq1.xml","form_type":"4"}},{"id":917585,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44678,"kind":"person","name":"Cashman Neil","position":1,"cik":"0001927064","reported_name":"Cashman Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Shares","published_at":"2026-02-06T01:41:16.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":4122,"price":12.13,"value":49999.86,"ownership":{"direct":false,"nature":"By Research Capital Corporation"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 4,122 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 4,122 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 4,122 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 4,122 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."}],"balance_after":4122,"source":{"system":"sec-edgar","filing":"0001104659-26-011140","document":"tm265402-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926011140/tm265402-5_4seq1.xml","form_type":"4"}},{"id":917584,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":25410,"kind":"person","name":"Kaplan Johanne","position":1,"cik":"0001967717","reported_name":"Kaplan Johanne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Warrants to purchase Common Shares","published_at":"2026-02-06T01:40:29.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":2060,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":2060,"derivative":{"exercise_price":14.4,"exercise_date":"2026-02-03","expiration_date":"2031-02-03","underlying":"Common Shares","underlying_shares":2060},"source":{"system":"sec-edgar","filing":"0001104659-26-011139","document":"tm265402-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926011139/tm265402-4_4seq1.xml","form_type":"4"}},{"id":917583,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":25410,"kind":"person","name":"Kaplan Johanne","position":1,"cik":"0001967717","reported_name":"Kaplan Johanne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Shares","published_at":"2026-02-06T01:40:29.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":2060,"price":12.13,"value":24987.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025."}],"balance_after":2312,"source":{"system":"sec-edgar","filing":"0001104659-26-011139","document":"tm265402-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926011139/tm265402-4_4seq1.xml","form_type":"4"}},{"id":917593,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44688,"kind":"person","name":"Warma Neil K","position":1,"cik":"0001437911","reported_name":"Warma Neil K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrants to purchase Common Shares","published_at":"2026-02-06T01:39:31.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":6183,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":6183,"derivative":{"exercise_price":14.4,"exercise_date":"2026-02-03","expiration_date":"2031-02-03","underlying":"Common Shares","underlying_shares":6183},"source":{"system":"sec-edgar","filing":"0001104659-26-011138","document":"tm265402-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437911/000110465926011138/tm265402-3_4seq1.xml","form_type":"4"}},{"id":917592,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44688,"kind":"person","name":"Warma Neil K","position":1,"cik":"0001437911","reported_name":"Warma Neil K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-02-06T01:39:31.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":6183,"price":12.13,"value":74999.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."}],"balance_after":6183,"source":{"system":"sec-edgar","filing":"0001104659-26-011138","document":"tm265402-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437911/000110465926011138/tm265402-3_4seq1.xml","form_type":"4"}},{"id":917582,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44677,"kind":"person","name":"Milbury Max A.","position":1,"cik":"0001927056","reported_name":"Milbury Max A.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Principal Accounting Officer"}}],"security":"Warrants to purchase Common Shares","published_at":"2026-02-06T01:37:52.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":6595,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":6595,"derivative":{"exercise_price":14.4,"exercise_date":"2026-02-03","expiration_date":"2031-02-03","underlying":"Common Shares","underlying_shares":6595},"source":{"system":"sec-edgar","filing":"0001104659-26-011137","document":"tm265402-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926011137/tm265402-2_4seq1.xml","form_type":"4"}},{"id":917581,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44677,"kind":"person","name":"Milbury Max A.","position":1,"cik":"0001927056","reported_name":"Milbury Max A.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Principal Accounting Officer"}}],"security":"Common Shares","published_at":"2026-02-06T01:37:52.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":6595,"price":12.13,"value":79997.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025."}],"balance_after":8409,"source":{"system":"sec-edgar","filing":"0001104659-26-011137","document":"tm265402-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926011137/tm265402-2_4seq1.xml","form_type":"4"}},{"id":917580,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":51471,"kind":"person","name":"Kirwin Patrick D.","position":1,"cik":"0001927062","reported_name":"Kirwin Patrick D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase Common Shares","published_at":"2026-02-06T01:36:47.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":3050,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":3050,"derivative":{"exercise_price":14.4,"exercise_date":"2026-02-03","expiration_date":"2031-02-03","underlying":"Common Shares","underlying_shares":3050},"source":{"system":"sec-edgar","filing":"0001104659-26-011135","document":"tm265402d1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926011135/tm265402d1_4seq1.xml","form_type":"4"}},{"id":917579,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":51471,"kind":"person","name":"Kirwin Patrick D.","position":1,"cik":"0001927062","reported_name":"Kirwin Patrick D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-02-06T01:36:47.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":3050,"price":12.13,"value":36996.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the \"Common Shares\") and Common Share purchase warrants (the \"Common Share Warrants\") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025."}],"balance_after":5135,"source":{"system":"sec-edgar","filing":"0001104659-26-011135","document":"tm265402d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926011135/tm265402d1_4seq1.xml","form_type":"4"}},{"id":917713,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":67584,"kind":"organization","name":"ABG Management Ltd.","position":1,"cik":"0001832106","reported_name":"ABG Management Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67585,"kind":"organization","name":"Ally Bridge MedAlpha Master Fund L.P.","position":2,"cik":"0001831963","reported_name":"Ally Bridge MedAlpha Master Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67586,"kind":"organization","name":"Ally Bridge Group (NY) LLC","position":3,"cik":"0001822947","reported_name":"Ally Bridge Group (NY) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67587,"kind":"person","name":"Yu Fan","position":4,"cik":"0001668029","reported_name":"Yu Fan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44676,"kind":"person","name":"Alex Slanix Paul","position":5,"cik":"0002092283","reported_name":"Alex Slanix Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2026-02-06T00:00:01.000Z","date":"2026-02-03","kind":"purchase","planned":false,"acquired":true,"shares":700741,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The warrants to purchase Common Shares (the \"Warrants\") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the \"Milestone Event\" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The warrants to purchase Common Shares (the \"Warrants\") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the \"Milestone Event\" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited."}],"balance_after":700741,"derivative":{"exercise_price":14.4,"underlying":"Common Shares","underlying_shares":700741},"source":{"system":"sec-edgar","filing":"0001493152-26-005410","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668029/000149315226005410/ownership.xml","form_type":"4"}},{"id":917712,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":67584,"kind":"organization","name":"ABG Management Ltd.","position":1,"cik":"0001832106","reported_name":"ABG Management Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67585,"kind":"organization","name":"Ally Bridge MedAlpha Master Fund L.P.","position":2,"cik":"0001831963","reported_name":"Ally Bridge MedAlpha Master Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67586,"kind":"organization","name":"Ally Bridge Group (NY) LLC","position":3,"cik":"0001822947","reported_name":"Ally Bridge Group (NY) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67587,"kind":"person","name":"Yu Fan","position":4,"cik":"0001668029","reported_name":"Yu Fan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44676,"kind":"person","name":"Alex Slanix Paul","position":5,"cik":"0002092283","reported_name":"Alex Slanix Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-02-06T00:00:01.000Z","date":"2026-02-03","kind":"purchase","planned":false,"acquired":true,"shares":700741,"price":12.13,"value":8499988.33,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited."}],"balance_after":943090,"source":{"system":"sec-edgar","filing":"0001493152-26-005410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668029/000149315226005410/ownership.xml","form_type":"4"}},{"id":1013832,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":67584,"kind":"organization","name":"ABG Management Ltd.","position":1,"cik":"0001832106","reported_name":"ABG Management Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67585,"kind":"organization","name":"Ally Bridge MedAlpha Master Fund L.P.","position":2,"cik":"0001831963","reported_name":"Ally Bridge MedAlpha Master Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67586,"kind":"organization","name":"Ally Bridge Group (NY) LLC","position":3,"cik":"0001822947","reported_name":"Ally Bridge Group (NY) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67587,"kind":"person","name":"Yu Fan","position":4,"cik":"0001668029","reported_name":"Yu Fan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44676,"kind":"person","name":"Alex Slanix Paul","position":5,"cik":"0002092283","reported_name":"Alex Slanix Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-10-24T20:34:08.000Z","date":"2025-10-22","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option vested on the date of grant and the remaining shares shall vest in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This option was granted to Slanix Alex, a director of the Issuer and an employee of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. Dr. Alex holds any equity-based compensation awarded to him for his service as a director of the Issuer for the benefit of Ally Bridge MedAlpha Master Fund L.P. Any proceeds from the sale of shares upon exercise of this award shall be remitted to Ally Bridge MedAlpha Master Fund L.P. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such securities are beneficially owned by him for Section 16 or any other purpose."}],"balance_after":40000,"derivative":{"exercise_price":0.45,"expiration_date":"2035-10-22","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001493152-25-019320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668029/000149315225019320/ownership.xml","form_type":"4"}},{"id":1022910,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44677,"kind":"person","name":"Milbury Max A.","position":1,"cik":"0001927056","reported_name":"Milbury Max A.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Principal Accounting Officer"}}],"security":"Common Shares","published_at":"2025-10-06T13:12:38.000Z","date":"2025-10-03","kind":"purchase","planned":false,"acquired":true,"shares":30392,"price":0.4912,"value":14928.5504,"ownership":{"direct":true},"balance_after":45389,"source":{"system":"sec-edgar","filing":"0001927056-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000192705625000004/primary_doc.xml","form_type":"4"}},{"id":1030501,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":74833,"kind":"organization","name":"Jeremy M. Sclar 2012 Irrevocable Family Trust","position":1,"cik":"0002089163","reported_name":"Jeremy M. Sclar 2012 Irrevocable Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Shares","published_at":"2025-09-30T20:17:04.000Z","date":"2025-07-29","kind":"purchase","planned":false,"acquired":true,"shares":3139533,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance."}],"balance_after":3139533,"derivative":{"underlying":"Common Shares","underlying_shares":3139533},"source":{"system":"sec-edgar","filing":"0001104659-25-095035","document":"tm2523607-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925095035/tm2523607-3_4seq1.xml","form_type":"4"}},{"id":1030500,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":74833,"kind":"organization","name":"Jeremy M. Sclar 2012 Irrevocable Family Trust","position":1,"cik":"0002089163","reported_name":"Jeremy M. Sclar 2012 Irrevocable Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche C Common Share Purchase Warrants","published_at":"2025-09-30T20:17:04.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":697674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":697674},"source":{"system":"sec-edgar","filing":"0001104659-25-095035","document":"tm2523607-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925095035/tm2523607-3_4seq1.xml","form_type":"4"}},{"id":1030499,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":74833,"kind":"organization","name":"Jeremy M. Sclar 2012 Irrevocable Family Trust","position":1,"cik":"0002089163","reported_name":"Jeremy M. Sclar 2012 Irrevocable Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche B Common Share Purchase Warrants","published_at":"2025-09-30T20:17:04.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":697674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":697674},"source":{"system":"sec-edgar","filing":"0001104659-25-095035","document":"tm2523607-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925095035/tm2523607-3_4seq1.xml","form_type":"4"}},{"id":1030498,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":74833,"kind":"organization","name":"Jeremy M. Sclar 2012 Irrevocable Family Trust","position":1,"cik":"0002089163","reported_name":"Jeremy M. Sclar 2012 Irrevocable Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche A Common Share Purchase Warrants","published_at":"2025-09-30T20:17:04.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":697674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the \"JS Trust\") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the \"JS Trust\") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the \"JS Trust\") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":697674},"source":{"system":"sec-edgar","filing":"0001104659-25-095035","document":"tm2523607-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925095035/tm2523607-3_4seq1.xml","form_type":"4"}},{"id":1030497,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":74833,"kind":"organization","name":"Jeremy M. Sclar 2012 Irrevocable Family Trust","position":1,"cik":"0002089163","reported_name":"Jeremy M. Sclar 2012 Irrevocable Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-09-30T20:17:04.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":697674,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."}],"balance_after":3710459,"source":{"system":"sec-edgar","filing":"0001104659-25-095035","document":"tm2523607-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925095035/tm2523607-3_4seq1.xml","form_type":"4"}},{"id":1030496,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":74833,"kind":"organization","name":"Jeremy M. Sclar 2012 Irrevocable Family Trust","position":1,"cik":"0002089163","reported_name":"Jeremy M. Sclar 2012 Irrevocable Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-09-30T20:17:04.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":697674,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."}],"balance_after":3012785,"source":{"system":"sec-edgar","filing":"0001104659-25-095035","document":"tm2523607-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925095035/tm2523607-3_4seq1.xml","form_type":"4"}},{"id":1030495,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":74833,"kind":"organization","name":"Jeremy M. Sclar 2012 Irrevocable Family Trust","position":1,"cik":"0002089163","reported_name":"Jeremy M. Sclar 2012 Irrevocable Family Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-09-30T20:17:04.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":697674,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the \"JS Trust\") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the \"JS Trust\") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."}],"balance_after":2315111,"source":{"system":"sec-edgar","filing":"0001104659-25-095035","document":"tm2523607-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925095035/tm2523607-3_4seq1.xml","form_type":"4"}},{"id":1032945,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44688,"kind":"person","name":"Warma Neil K","position":1,"cik":"0001437911","reported_name":"Warma Neil K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2025-09-24T12:58:33.000Z","date":"2025-09-22","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months"}],"balance_after":600000,"derivative":{"exercise_price":0.45,"expiration_date":"2035-09-22","underlying":"Common Shares","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001437911-25-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437911/000143791125000002/primary_doc.xml","form_type":"4"}},{"id":1032940,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44677,"kind":"person","name":"Milbury Max A.","position":1,"cik":"0001927056","reported_name":"Milbury Max A.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Principal Accounting Officer"}}],"security":"Option (right to buy)","published_at":"2025-09-24T12:54:53.000Z","date":"2025-09-22","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months"}],"balance_after":60000,"derivative":{"exercise_price":0.45,"expiration_date":"2035-09-22","underlying":"Common Shares","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001927056-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000192705625000003/primary_doc.xml","form_type":"4"}},{"id":1032939,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44678,"kind":"person","name":"Cashman Neil","position":1,"cik":"0001927064","reported_name":"Cashman Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2025-09-24T12:51:55.000Z","date":"2025-09-22","kind":"grant","planned":false,"acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months"}],"balance_after":165000,"derivative":{"exercise_price":0.45,"expiration_date":"2035-09-22","underlying":"Common Shares","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001927064-25-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000192706425000002/primary_doc.xml","form_type":"4"}},{"id":1032938,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":25410,"kind":"person","name":"Kaplan Johanne","position":1,"cik":"0001967717","reported_name":"Kaplan Johanne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Option (right to buy)","published_at":"2025-09-24T12:48:42.000Z","date":"2025-09-22","kind":"grant","planned":false,"acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months"}],"balance_after":165000,"derivative":{"exercise_price":0.45,"expiration_date":"2035-09-22","underlying":"Common Shares","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001967717-25-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000196771725000002/primary_doc.xml","form_type":"4"}},{"id":1032936,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":74994,"kind":"person","name":"ALTSTIEL LARRY DOUGLAS","position":1,"cik":"0001619444","reported_name":"ALTSTIEL LARRY DOUGLAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Option (right to buy)","published_at":"2025-09-24T12:45:58.000Z","date":"2025-09-22","kind":"grant","planned":false,"acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months"}],"balance_after":165000,"derivative":{"exercise_price":0.45,"expiration_date":"2035-09-22","underlying":"Common Shares","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001619444-25-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000161944425000002/primary_doc.xml","form_type":"4"}},{"id":1045754,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":75665,"kind":"person","name":"Sclar Jeremy M.","position":1,"cik":"0001955608","reported_name":"Sclar Jeremy M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Shares","published_at":"2025-09-08T20:10:26.000Z","date":"2025-07-29","kind":"purchase","planned":false,"acquired":true,"shares":3139533,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust."}],"balance_after":3139533,"derivative":{"underlying":"Common Shares","underlying_shares":3139533},"source":{"system":"sec-edgar","filing":"0001104659-25-088246","document":"tm2522972-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925088246/tm2522972-1_4seq1.xml","form_type":"4"}},{"id":1045753,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":75665,"kind":"person","name":"Sclar Jeremy M.","position":1,"cik":"0001955608","reported_name":"Sclar Jeremy M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche C Common Share Purchase Warrants","published_at":"2025-09-08T20:10:26.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":697674,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":697674},"source":{"system":"sec-edgar","filing":"0001104659-25-088246","document":"tm2522972-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925088246/tm2522972-1_4seq1.xml","form_type":"4"}},{"id":1045752,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":75665,"kind":"person","name":"Sclar Jeremy M.","position":1,"cik":"0001955608","reported_name":"Sclar Jeremy M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche B Common Share Purchase Warrants","published_at":"2025-09-08T20:10:26.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":697674,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":697674},"source":{"system":"sec-edgar","filing":"0001104659-25-088246","document":"tm2522972-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925088246/tm2522972-1_4seq1.xml","form_type":"4"}},{"id":1045751,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":75665,"kind":"person","name":"Sclar Jeremy M.","position":1,"cik":"0001955608","reported_name":"Sclar Jeremy M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche A Common Share Purchase Warrants","published_at":"2025-09-08T20:10:26.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":697674,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the \"JS Trust\") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the \"JS Trust\") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the \"JS Trust\") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":697674},"source":{"system":"sec-edgar","filing":"0001104659-25-088246","document":"tm2522972-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925088246/tm2522972-1_4seq1.xml","form_type":"4"}},{"id":1045750,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":75665,"kind":"person","name":"Sclar Jeremy M.","position":1,"cik":"0001955608","reported_name":"Sclar Jeremy M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-09-08T20:10:26.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":697674,"ownership":{"direct":false,"nature":"By JS Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust."}],"balance_after":3710459,"source":{"system":"sec-edgar","filing":"0001104659-25-088246","document":"tm2522972-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925088246/tm2522972-1_4seq1.xml","form_type":"4"}},{"id":1045749,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":75665,"kind":"person","name":"Sclar Jeremy M.","position":1,"cik":"0001955608","reported_name":"Sclar Jeremy M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-09-08T20:10:26.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":697674,"ownership":{"direct":false,"nature":"By JS Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust."}],"balance_after":3012785,"source":{"system":"sec-edgar","filing":"0001104659-25-088246","document":"tm2522972-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925088246/tm2522972-1_4seq1.xml","form_type":"4"}},{"id":1045748,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":75665,"kind":"person","name":"Sclar Jeremy M.","position":1,"cik":"0001955608","reported_name":"Sclar Jeremy M.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-09-08T20:10:26.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":697674,"ownership":{"direct":false,"nature":"By: Jeremy M. Sclar 2012 Irrevocable Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the \"JS Trust\") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the \"JS Trust\") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust."}],"balance_after":2315111,"source":{"system":"sec-edgar","filing":"0001104659-25-088246","document":"tm2522972-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925088246/tm2522972-1_4seq1.xml","form_type":"4"}},{"id":1066791,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks section."}}],"security":"Tranche C Common Share Purchase Warrants","published_at":"2025-08-14T20:17:09.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-078631","document":"tm2523440-4_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925078631/tm2523440-4_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-07-29"}},{"id":1066790,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks section."}}],"security":"Tranche B Common Share Purchase Warrants","published_at":"2025-08-14T20:17:09.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-078631","document":"tm2523440-4_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925078631/tm2523440-4_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-07-29"}},{"id":1066789,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks section."}}],"security":"Tranche A Common Share Purchase Warrants","published_at":"2025-08-14T20:17:09.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-078631","document":"tm2523440-4_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925078631/tm2523440-4_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-07-29"}},{"id":1066788,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks section."}}],"security":"Common Shares, no par value","published_at":"2025-08-14T20:15:35.000Z","date":"2025-03-13","kind":"other","planned":false,"acquired":false,"shares":48333,"ownership":{"direct":false,"nature":"By Title 19 Acies"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 13, 2025, the ownership of Title 19 Acies, a series of a Delaware limited liability company, was assigned to Skye Peak Partners LLC, a Delaware limited liability company (\"SPP\"), effective as of January 1, 2025. In connection with such assignment, the management of Title 19 Acies changed from the Reporting Person as sole manager to Emmett Gordon and Michael Youniss as managers, and the Reporting Person does not otherwise have investment control over the shares of the Issuer held by SPP. Accordingly, the Reporting Person no longer has a pecuniary interest in shares of the Issuer held by Title 19 Acies."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 13, 2025, the ownership of Title 19 Acies, a series of a Delaware limited liability company, was assigned to Skye Peak Partners LLC, a Delaware limited liability company (\"SPP\"), effective as of January 1, 2025. In connection with such assignment, the management of Title 19 Acies changed from the Reporting Person as sole manager to Emmett Gordon and Michael Youniss as managers, and the Reporting Person does not otherwise have investment control over the shares of the Issuer held by SPP. Accordingly, the Reporting Person no longer has a pecuniary interest in shares of the Issuer held by Title 19 Acies."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Acies, of which the Reporting Person was the sole manager."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-078615","document":"tm2523440-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925078615/tm2523440-2_4seq1.xml","form_type":"4"}},{"id":1066692,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks section."}}],"security":"Tranche C Common Share Purchase Warrants","published_at":"2025-08-14T16:18:12.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-078637","document":"tm2523440-3_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925078637/tm2523440-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-07-29"}},{"id":1066691,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks section."}}],"security":"Tranche B Common Share Purchase Warrants","published_at":"2025-08-14T16:18:12.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-078637","document":"tm2523440-3_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925078637/tm2523440-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-07-29"}},{"id":1066690,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks section."}}],"security":"Tranche A Common Share Purchase Warrants","published_at":"2025-08-14T16:18:12.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-078637","document":"tm2523440-3_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925078637/tm2523440-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-07-29"}},{"id":1080019,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Shares","published_at":"2025-07-30T00:20:23.000Z","date":"2025-07-29","kind":"purchase","planned":false,"acquired":true,"shares":539100,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":539100,"derivative":{"underlying":"Common Shares","underlying_shares":539100},"source":{"system":"sec-edgar","filing":"0001104659-25-071858","document":"tm2521929-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925071858/tm2521929-2_4seq1.xml","form_type":"4"}},{"id":1080018,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche C Common Share Purchase Warrants","published_at":"2025-07-30T00:20:23.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-071858","document":"tm2521929-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925071858/tm2521929-2_4seq1.xml","form_type":"4"}},{"id":1080017,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche B Common Share Purchase Warrants","published_at":"2025-07-30T00:20:23.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-071858","document":"tm2521929-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925071858/tm2521929-2_4seq1.xml","form_type":"4"}},{"id":1080016,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche A Common Share Purchase Warrants","published_at":"2025-07-30T00:20:23.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-071858","document":"tm2521929-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925071858/tm2521929-2_4seq1.xml","form_type":"4"}},{"id":1080015,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-07-30T00:20:23.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":119800,"ownership":{"direct":false,"nature":"By Title 19 Promis"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":2435029,"source":{"system":"sec-edgar","filing":"0001104659-25-071858","document":"tm2521929-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925071858/tm2521929-2_4seq1.xml","form_type":"4"}},{"id":1080014,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-07-30T00:20:23.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":119800,"ownership":{"direct":false,"nature":"By Title 19 Promis"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":2315229,"source":{"system":"sec-edgar","filing":"0001104659-25-071858","document":"tm2521929-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925071858/tm2521929-2_4seq1.xml","form_type":"4"}},{"id":1080013,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-07-30T00:20:23.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":119800,"ownership":{"direct":false,"nature":"By Title 19 Promis"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":2195429,"source":{"system":"sec-edgar","filing":"0001104659-25-071858","document":"tm2521929-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925071858/tm2521929-2_4seq1.xml","form_type":"4"}},{"id":1079876,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Shares","published_at":"2025-07-29T20:18:49.000Z","date":"2025-07-29","kind":"purchase","planned":false,"acquired":true,"shares":539100,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."}],"balance_after":539100,"derivative":{"underlying":"Common Shares","underlying_shares":539100},"source":{"system":"sec-edgar","filing":"0001104659-25-071857","document":"tm2521929-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925071857/tm2521929-1_4seq1.xml","form_type":"4"}},{"id":1079875,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche C Common Share Purchase Warrants","published_at":"2025-07-29T20:18:49.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-071857","document":"tm2521929-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925071857/tm2521929-1_4seq1.xml","form_type":"4"}},{"id":1079874,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche B Common Share Purchase Warrants","published_at":"2025-07-29T20:18:49.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-071857","document":"tm2521929-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925071857/tm2521929-1_4seq1.xml","form_type":"4"}},{"id":1079873,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche A Common Share Purchase Warrants","published_at":"2025-07-29T20:18:49.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-071857","document":"tm2521929-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925071857/tm2521929-1_4seq1.xml","form_type":"4"}},{"id":1079872,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-07-29T20:18:49.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":119800,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."}],"balance_after":2435029,"source":{"system":"sec-edgar","filing":"0001104659-25-071857","document":"tm2521929-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925071857/tm2521929-1_4seq1.xml","form_type":"4"}},{"id":1079871,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-07-29T20:18:49.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":119800,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":2315229,"source":{"system":"sec-edgar","filing":"0001104659-25-071857","document":"tm2521929-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925071857/tm2521929-1_4seq1.xml","form_type":"4"}},{"id":1079870,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-07-29T20:18:49.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":119800,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":2195429,"source":{"system":"sec-edgar","filing":"0001104659-25-071857","document":"tm2521929-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925071857/tm2521929-1_4seq1.xml","form_type":"4"}},{"id":1096089,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-07-02T20:15:22.000Z","date":"2025-06-30","kind":"sale","planned":false,"acquired":false,"shares":93223,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2025, the reporting person contributed 93,223 shares of common stock of the Issuer held by the reporting person to Skye Peak Partners LLC, a Delaware limited liability company (\"SPP\"), in exchange for membership interests of SPP."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-065292","document":"tm2519639-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925065292/tm2519639-1_4seq1.xml","form_type":"4"}},{"id":1109999,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":26284,"kind":"person","name":"Mandel-Brehm Josh","position":1,"cik":"0001927058","reported_name":"Mandel-Brehm Josh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-06-16T21:23:07.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in full on the earlier of the first anniversary of the Grant Date and June 12, 2026, subject to continued service on the Board."}],"balance_after":20000,"derivative":{"exercise_price":0.5,"expiration_date":"2035-06-12","underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001374339-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927058/000137433925000006/primary_doc.xml","form_type":"4"}},{"id":1109675,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":51471,"kind":"person","name":"Kirwin Patrick D.","position":1,"cik":"0001927062","reported_name":"Kirwin Patrick D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-06-16T21:11:49.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in full on the earlier of the first anniversary of the Grant Date and June 12, 2026, subject to continued service on the Board."}],"balance_after":20000,"derivative":{"exercise_price":0.5,"expiration_date":"2035-06-12","underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001374339-25-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000137433925000005/primary_doc.xml","form_type":"4"}},{"id":1109674,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44679,"kind":"person","name":"Shafmaster Madge K.","position":1,"cik":"0001927066","reported_name":"Shafmaster Madge K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-06-16T21:04:40.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in full on the earlier of the first anniversary of the Grant Date and June 12, 2026, subject to continued service on the Board."}],"balance_after":20000,"derivative":{"exercise_price":0.5,"expiration_date":"2035-06-12","underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001374339-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000137433925000004/primary_doc.xml","form_type":"4"}},{"id":1110289,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44879,"kind":"person","name":"WYMAN WILLIAM W","position":1,"cik":"0001077644","reported_name":"WYMAN WILLIAM W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-06-16T20:57:59.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in full on the earlier of the first anniversary of the Grant Date and June 12, 2026, subject to continued service on the Board."}],"balance_after":20000,"derivative":{"exercise_price":0.5,"expiration_date":"2035-06-12","underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001374339-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1077644/000137433925000003/primary_doc.xml","form_type":"4"}},{"id":1109673,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44680,"kind":"person","name":"Williams Eugene","position":1,"cik":"0001927626","reported_name":"Williams Eugene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-06-16T20:45:42.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest in full on the earlier of the first anniversary of the Grant Date and June 12, 2026, subject to continued service on the Board."}],"balance_after":20000,"derivative":{"exercise_price":0.5,"expiration_date":"2035-06-12","underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001374339-25-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000137433925000002/primary_doc.xml","form_type":"4"}},{"id":1271433,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44678,"kind":"person","name":"Cashman Neil","position":1,"cik":"0001927064","reported_name":"Cashman Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Shares","published_at":"2025-02-12T22:21:35.000Z","date":"2025-02-10","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":0.973,"value":14595.0,"ownership":{"direct":false,"nature":"By his spouse"},"balance_after":16617,"source":{"system":"sec-edgar","filing":"0001374339-25-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000137433925000001/primary_doc.xml","form_type":"4"}},{"id":1357095,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44677,"kind":"person","name":"Milbury Max A.","position":1,"cik":"0001927056","reported_name":"Milbury Max A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Option (right to buy)","published_at":"2024-11-21T00:04:11.000Z","date":"2024-11-18","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest on November 18, 2025, and the balance shall vest ratably over 36 months."}],"balance_after":70000,"derivative":{"exercise_price":1,"expiration_date":"2034-11-18","underlying":"Common Shares","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001104659-24-121136","document":"tm2429073-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465924121136/tm2429073-4_4seq1.xml","form_type":"4"}},{"id":1357094,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":25410,"kind":"person","name":"Kaplan Johanne","position":1,"cik":"0001967717","reported_name":"Kaplan Johanne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Option (right to buy)","published_at":"2024-11-21T00:03:06.000Z","date":"2024-11-18","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest on November 18, 2025, and the balance shall vest ratably over 36 months."}],"balance_after":175000,"derivative":{"exercise_price":1,"expiration_date":"2034-11-18","underlying":"Common Shares","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001104659-24-121135","document":"tm2429073-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465924121135/tm2429073-3_4seq1.xml","form_type":"4"}},{"id":1357093,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44678,"kind":"person","name":"Cashman Neil","position":1,"cik":"0001927064","reported_name":"Cashman Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2024-11-21T00:02:09.000Z","date":"2024-11-18","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest on November 18, 2025, and the balance shall vest ratably over 36 months."}],"balance_after":200000,"derivative":{"exercise_price":1,"expiration_date":"2034-11-18","underlying":"Common Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001104659-24-121133","document":"tm2429073-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465924121133/tm2429073-2_4seq1.xml","form_type":"4"}},{"id":1357092,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":74994,"kind":"person","name":"ALTSTIEL LARRY DOUGLAS","position":1,"cik":"0001619444","reported_name":"ALTSTIEL LARRY DOUGLAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Option (right to buy)","published_at":"2024-11-21T00:01:13.000Z","date":"2024-11-18","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest on November 18, 2025, and the balance shall vest ratably over 36 months."}],"balance_after":175000,"derivative":{"exercise_price":1,"expiration_date":"2034-11-18","underlying":"Common Shares","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001104659-24-121132","document":"tm2429073-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465924121132/tm2429073-1_4seq1.xml","form_type":"4"}},{"id":1388074,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44688,"kind":"person","name":"Warma Neil K","position":1,"cik":"0001437911","reported_name":"Warma Neil K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2024-10-10T21:03:35.000Z","date":"2024-10-08","kind":"grant","planned":false,"acquired":true,"shares":490338,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance Award shall vest 25% on the date that the 10-day VWAP of the Common Shares on the Nasdaq Capital Market exceeds three times the exercise price, $3.45, with the remainder vesting ratably over the following thirty-six months"}],"balance_after":1842739,"derivative":{"exercise_price":1.15,"expiration_date":"2034-10-08","underlying":"Common Shares","underlying_shares":490338},"source":{"system":"sec-edgar","filing":"0001374339-24-000004","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437911/000137433924000004/primary_doc.xml","form_type":"4"}},{"id":1388073,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44688,"kind":"person","name":"Warma Neil K","position":1,"cik":"0001437911","reported_name":"Warma Neil K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2024-10-10T21:03:35.000Z","date":"2024-10-08","kind":"grant","planned":false,"acquired":true,"shares":1144122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Initial Award is 25% vested upon grant with the remaining shares vesting ratably over thirty-six months"}],"balance_after":1352455,"derivative":{"exercise_price":1.15,"expiration_date":"2034-10-08","underlying":"Common Shares","underlying_shares":1144122},"source":{"system":"sec-edgar","filing":"0001374339-24-000004","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437911/000137433924000004/primary_doc.xml","form_type":"4"}},{"id":1390328,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44879,"kind":"person","name":"WYMAN WILLIAM W","position":1,"cik":"0001077644","reported_name":"WYMAN WILLIAM W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-10-07T22:41:35.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33% of the shares subject to this option vested on October 3, 2024, and the balance shall vest ratably over the following 24 months, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.11,"expiration_date":"2034-10-03","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-24-106770","document":"tm2425760-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1077644/000110465924106770/tm2425760-5_4seq1.xml","form_type":"4"}},{"id":1389986,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44680,"kind":"person","name":"Williams Eugene","position":1,"cik":"0001927626","reported_name":"Williams Eugene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-10-07T22:40:35.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33% of the shares subject to this option vested on October 3, 2024, and the balance shall vest ratably over the following 24 months, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.11,"expiration_date":"2034-10-03","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-24-106769","document":"tm2425760-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465924106769/tm2425760-4_4seq1.xml","form_type":"4"}},{"id":1389985,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44679,"kind":"person","name":"Shafmaster Madge K.","position":1,"cik":"0001927066","reported_name":"Shafmaster Madge K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-10-07T22:39:35.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33% of the shares subject to this option vested on October 3, 2024, and the balance shall vest ratably over the following 24 months, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.11,"expiration_date":"2034-10-03","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-24-106768","document":"tm2425760-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465924106768/tm2425760-3_4seq1.xml","form_type":"4"}},{"id":1390247,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":26284,"kind":"person","name":"Mandel-Brehm Josh","position":1,"cik":"0001927058","reported_name":"Mandel-Brehm Josh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-10-07T22:38:16.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33% of the shares subject to this option vested on October 3, 2024, and the balance shall vest ratably over the following 24 months, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.11,"expiration_date":"2034-10-03","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-24-106767","document":"tm2425760-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927058/000110465924106767/tm2425760-2_4seq1.xml","form_type":"4"}},{"id":1389984,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":51471,"kind":"person","name":"Kirwin Patrick D.","position":1,"cik":"0001927062","reported_name":"Kirwin Patrick D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-10-07T22:36:58.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33% of the shares subject to this option vested on October 3, 2024, and the balance shall vest ratably over the following 24 months, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.11,"expiration_date":"2034-10-03","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-24-106766","document":"tm2425760-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465924106766/tm2425760-1_4seq1.xml","form_type":"4"}},{"id":1400060,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44679,"kind":"person","name":"Shafmaster Madge K.","position":1,"cik":"0001927066","reported_name":"Shafmaster Madge K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-09-24T22:56:35.000Z","date":"2024-09-24","kind":"purchase","planned":false,"acquired":true,"shares":70000,"price":1.3004,"value":91028.0,"ownership":{"direct":true},"balance_after":208333,"source":{"system":"sec-edgar","filing":"0001374339-24-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000137433924000003/primary_doc.xml","form_type":"4"}},{"id":1400059,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44679,"kind":"person","name":"Shafmaster Madge K.","position":1,"cik":"0001927066","reported_name":"Shafmaster Madge K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-09-24T22:56:35.000Z","date":"2024-09-23","kind":"purchase","planned":false,"acquired":true,"shares":70000,"price":1.2808,"value":89656.0,"ownership":{"direct":true},"balance_after":138333,"source":{"system":"sec-edgar","filing":"0001374339-24-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000137433924000003/primary_doc.xml","form_type":"4"}},{"id":1400058,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":44679,"kind":"person","name":"Shafmaster Madge K.","position":1,"cik":"0001927066","reported_name":"Shafmaster Madge K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-09-24T22:56:35.000Z","date":"2024-09-20","kind":"purchase","planned":false,"acquired":true,"shares":60000,"price":1.2511,"value":75066.0,"ownership":{"direct":true},"balance_after":68333,"source":{"system":"sec-edgar","filing":"0001374339-24-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000137433924000003/primary_doc.xml","form_type":"4"}},{"id":1403967,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2024-09-18T20:15:05.000Z","date":"2024-09-17","kind":"purchase","planned":false,"acquired":true,"shares":16292,"price":1.4,"value":22808.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in four separate transactions, with prices ranging from $1.37 to $1.40 for an average weighted purchase price of $1.40. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased in each transaction."}],"balance_after":93223,"source":{"system":"sec-edgar","filing":"0001104659-24-100976","document":"tm2424268-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465924100976/tm2424268-1_4seq1.xml","form_type":"4"}},{"id":1403966,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2024-09-18T20:15:05.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":76931,"price":1.2228,"value":94071.2268,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in forty-two separate transactions, with prices ranging from $1.1200 to $1.3700 for an average weighted purchase price of $1.2228 rounded to the nearest ten thousandth. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased in each transaction."}],"balance_after":76931,"source":{"system":"sec-edgar","filing":"0001104659-24-100976","document":"tm2424268-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465924100976/tm2424268-1_4seq1.xml","form_type":"4"}},{"id":1431208,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":51471,"kind":"person","name":"Kirwin Patrick D.","position":1,"cik":"0001927062","reported_name":"Kirwin Patrick D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-08-16T11:38:34.000Z","date":"2024-08-14","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.2492,"value":12492.0,"ownership":{"direct":true},"balance_after":62983,"source":{"system":"sec-edgar","filing":"0001374339-24-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374339/000137433924000002/primary_doc.xml","form_type":"4"}}],"next_cursor":"2024-08-16T11:38:34.000000Z,1431208"}